Effects of glucagon-like peptide-1 on endothelial function
in type 2 diabetes patients with stable coronary artery disease

Thomas Nyström,1 Mark K. Gutniak,† Qimin Zhang,1
Fan Zhang,1 Jens Juul Holst,2 Bo Ahre´n,3 and A˚ke Sjöholm1

1Department of Internal Medicine, Stockholm South Hospital, Karolinska Institutet,
Stockholm SE-118 83, Sweden; 2Department of Medical Physiology, Panum Institute, University of Copenhagen,
DK-1171 Copenhagen, Denmark; and 3Department of Medicine, Lund University, 221 00 Lund, Sweden

Submitted 3 June 2004; accepted in final form 11 August 2004

Nyström, Thomas, Mark K. Gutniak, Qimin Zhang, Fan
Zhang, Jens Juul Holst, Bo Ahre´n, and A˚ke Sjöholm. Effects of
glucagon-like peptide-1 on endothelial function in type 2 diabetes
patients with stable coronary artery disease. Am J Physiol Endocrinol
doi:10.1152/ajpendo.00237.2004.—GLP-1 stimulates insulin secre-
tion, suppresses glucagon secretion, delays gastric emptying, and
inhibits small bowel motility, all actions contributing to the anti-
diabetogenic peptide effect. Endothelial dysfunction is strongly asso-
ciated with insulin resistance and type 2 diabetes mellitus and may
cause the angiopathy typifying this debilitating disease. Therefore,
interventions affecting both endothelial dysfunction and insulin resis-
tance may prove useful in improving survival in type 2 diabetes
patients. We investigated GLP-1’s effect on endothelial function and
insulin resistance (SI) in two groups: 1) 12 type 2 diabetes patients
with stable coronary artery disease and 2) 10 healthy subjects with
normal endothelial function and SI. Subjects underwent infusion of
recombinant GLP-1 or saline in a random crossover study. Endothelial
function was measured by postischemic FMD of brachial artery, using
ultrasonography. SI [in (10−4 dl·kg−1·min−1)/(μU/ml)] was mea-
sured by hyperinsulinemic isoglycemic clamp technique. In type 2
diabetic subjects, GLP-1 infusion significantly increased relative
changes in brachial artery diameter from baseline FMD(%) (3.1 ± 0.6
vs. 6.6 ± 1.0%, P < 0.05), with no significant effects on SI (4.5 ± 0.8
vs. 5.2 ± 0.9, P = NS). In healthy subjects, GLP-1 infusion affected
neither FMD(%) (1.19 ± 0.9 vs. 10.3 ± 1.0%, P = NS) nor SI
(14.8 ± 1.8 vs. 11.6 ± 2.0, P = NS). We conclude that GLP-1
improves endothelial dysfunction but not insulin resistance in type 2
diabetic patients with coronary heart disease. This beneficial vascular
effect of GLP-1 adds yet another salutary property of the peptide
useful in diabetes treatment.

GLP-1 may be attributable to decreases in gastric and small bowel
motility, effects dependent on nitric oxide (NO) (31).

High-affinity receptors for GLP-1 are also present in extrapancreatic and intestinal tissues, i.e., nervous system, heart, kidney, and vascular smooth muscle (6, 22, 27). Apart from glycemic actions, cardiovascular effects by GLP-1 have been described. GLP-1 improves severe left ventricular heart failure in humans suffering from a myocardial infarction (24). Additionally, GLP-1 relaxes preconstricted pulmonary artery rings in rats, an effect described as NO dependent (17, 27). Recently, Yu et al. (34) demonstrated that GLP-1 infusion improves endothelial function in a salt sensitivity rat model (34). Endothelial function in response to reactive hyperemia can reliably be measured with ultrasonography, i.e., flow-mediated vasodi-
lation (FMD), and is considered to be NO mediated (10).

Furthermore, endothelial dysfunction of FMD in the brachial artery highly correlates with endothelial dysfunction in the coronary circulation (2). Endothelial dysfunction is strongly associated with insulin resistance and type 2 diabetes mellitus and may be causing the angiopathy typifying this debilitating disease (7). Intervention affecting both endothelial dysfunction and insulin resistance may prove useful in patients with type 2 diabetes.

Therefore, the aim of this study was to evaluate the effect of
GLP-1 on endothelial function in type 2 diabetic patients with coronary artery disease (CAD) and whether such an effect correlates to insulin sensitivity. Because there are differences in endothelial function between insulin-resistant subjects and healthy subjects, we also studied healthy subjects. Finally, we also investigated whether GLP-1 receptors are expressed on human coronary endothelial cells, an issue that remains elusive.

MATERIALS AND METHODS

Subjects

Twelve middle-aged, moderately obese Caucasian male patients with type 2 diabetes of short duration with an established CAD and 10 young, healthy, unmatched Caucasian male subjects participated in the study. Baseline characteristics of the study groups are shown in Table 1. The study was approved by the Karolinska Institutet ethics committee, and written informed consent from the study subjects was obtained.

The costs of publication of this article were defrayed in part by the payment
of page charges. The article must therefore be hereby marked "advertisement"
in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
GLP-1 was infused 15 min after priming for the hyperinsulminemic clamp and throughout the clamp, thus in total for 105 min. To assess as correctly as possible GLP-1 effects on sensitivity to insulin-mediated glucose disposal under the conditions normally prevailing in each patient, we chose to clamp patients at their actual fasting glucose levels (isoglycemic) rather than at statistically “normal” glucose levels (euglycemic). Thus the steady-state glucose level for diabetics is higher than that for controls. Another advantage of isoglycemic clamp is that one avoids artifacts caused by acute lowering of glucose levels.

**Brachial Artery Flow and Diameter**

The diameter of the target artery was measured from two-dimensional ultrasound images with a 7.0-MHz linear array transducer and a standard 128XP/10 system (Accuson, Mountain View, CA) according to the forearm cuff occlusion technique (9, 10). After a 30-min resting time, the subject’s left arm was immobilized, and the transducer was fixed in the same position throughout the study, with the assistance of a mechanical arm. The position of the transducer was marked to retrieve the same position of the artery in the second study. The brachial artery was scanned longitudinally, and the transmit (focus) zone was set to optimize images of the lumen arterial wall interface. The B-mode images were magnified by a resolution box and obtained with gating from the R wave of the electrocardiogram as triggering mode. The condition of reactive hyperemia was induced by inflation of a pneumatic tourniquet placed around the forearm to a pressure of 300 mmHg for 4.5 min, followed by release [endothelial-dependent vasodilation (FMD)]. Measurements were made at baseline (after 30 min of supine rest) and at 45 and 60 s after cuff release. Then, after 10 min of rest, 0.4 mg of glyceryl trinitrate spray was applied, and new images were obtained 4 min later [endothelial-independent vasodilation (nitroglycerin-mediated dilation; NTG)]. The relative changes in vessel diameter are expressed as percentages after reactive hyperemia [FMD(%)] and after nitroglycerine administration [NTG(%)], from baseline scan. Brachial artery diameter, the means of two images, was measured with an automated, computerized, analyzing system, according to the sonomorphological definition of Wendelhag et al. (32). In brief, this analyzing program is a PC/Windows-based software with digitized ultrasound image. The starting point of the measurement area is set by the operator, and a 10-mm box is automatically drawn. The different echo interfaces are automatically outlined. If obvious errors are detected, it is possible to modify the measurement by marking a correct echo in the ultrasound image. In this case, only one or two manually marked points are needed to guide the automatic system to the correct interface. This automated system has proven superior to manual measurement systems, with a dramatically improved reproducibility in both inter- and intraobserver coefficients of variation (32).

Arterial flow velocity rates were obtained with a pulsed Doppler signal at 70° angles to the vessel in the center of the artery. Ultrasound images were recorded 15 s after cuff release with the freeze mode. The volume flow was calculated by multiplying the velocity time integral of the Doppler flow signal for the mean of three pulse waves by the heart rate and vessel cross-sectional area. Calculations of blood flow

---

**Table 1. Baseline clinical and biochemical characteristics of the study groups**

<table>
<thead>
<tr>
<th>Clinical characteristics</th>
<th>Type 2 Diabetes Subjects (n = 12)</th>
<th>Healthy Subjects (n = 10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, yr</td>
<td>61 ± 3</td>
<td>29 ± 4</td>
</tr>
<tr>
<td>Duration of diabetes, yr</td>
<td>5 ± 1</td>
<td>5 ± 1</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>28 ± 1</td>
<td>24 ± 0.6</td>
</tr>
<tr>
<td>Smoker, yes/no</td>
<td>1/11</td>
<td>0/10</td>
</tr>
<tr>
<td>Systolic blood pressure, mmHg</td>
<td>126 ± 4</td>
<td>110 ± 2</td>
</tr>
<tr>
<td>Diastolic blood pressure, mmHg</td>
<td>78 ± 2</td>
<td>71 ± 2</td>
</tr>
<tr>
<td>Urinary protein, mg/l</td>
<td>71 ± 53</td>
<td>&lt;4</td>
</tr>
</tbody>
</table>

**Patients treated with**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Type 2 Diabetes</th>
<th>Healthy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insulin, yes/no</td>
<td>10/2</td>
<td>12/11</td>
</tr>
<tr>
<td>Insulin dose, units/day</td>
<td>52 ± 4</td>
<td>4/8</td>
</tr>
<tr>
<td>Sulfonylurea, yes/no</td>
<td>3/9</td>
<td>4/12</td>
</tr>
<tr>
<td>Metformin, yes/no</td>
<td>4/8</td>
<td>8/4</td>
</tr>
<tr>
<td>ACE inhibitor/ARB, yes/no</td>
<td>11/1</td>
<td>12/0</td>
</tr>
<tr>
<td>Beta-blocker, yes/no</td>
<td>12/0</td>
<td>8/4</td>
</tr>
<tr>
<td>Statin, yes/no</td>
<td>8/4</td>
<td>3/9</td>
</tr>
<tr>
<td>Acetyl salicylic acid, yes</td>
<td>12/0</td>
<td>0/1</td>
</tr>
</tbody>
</table>

**Biochemical characteristics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Type 2 Diabetes</th>
<th>Healthy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum hemoglobin, g/l</td>
<td>139 ± 3</td>
<td>146 ± 4</td>
</tr>
<tr>
<td>Serum creatinine, μmol/l</td>
<td>6.9 ± 0.4</td>
<td>4.5 ± 0.1</td>
</tr>
<tr>
<td>Serum total cholesterol, mmol/l</td>
<td>4.3 ± 0.2</td>
<td>3.8 ± 0.3</td>
</tr>
<tr>
<td>Serum HDL-cholesterol, mmol/l</td>
<td>0.9 ± 0.1</td>
<td>1.3 ± 0.2</td>
</tr>
<tr>
<td>Serum LDL-cholesterol, mmol/l</td>
<td>2.6 ± 0.1</td>
<td>2.0 ± 0.2</td>
</tr>
<tr>
<td>Serum triglycerides, mmol/l</td>
<td>1.7 ± 0.2</td>
<td>1.1 ± 0.2</td>
</tr>
</tbody>
</table>

Data are means ± SE. ARB, angiotensin receptor blocker; BMI, body mass index; ACE, ANG I-converting enzyme.

**Type 2 diabetes subjects.** In the diabetes group, three patients showed signs of microalbuminuria, but no one had any overt microvascular complications such as nephropathy, neuropathy, or retinopathy. However, they had all suffered a myocardial infarction. All but one were nonsmokers, and five were ex-smokers. All but one were non-snuff users. Lipid control was satisfactory, whereas glycemic control was moderately impaired. Eight subjects were on antihypertensive treatment. Everyone was receiving secondary preventive drugs against CAD. Metoprolol was the beta-blocker used in all patients. Drugs were withheld the evening before the experiments. Glycemic control was achieved by diet alone (in one patient) or diet plus oral hypoglycemic agents (metformin or sulfonylurea or both), or insulin alone or insulin plus oral hypoglycemic agents (Table 1). In all cases, 3–6 mo passed between the myocardial infarction and the commencement of the study procedure.

**Healthy subjects.** In the group of healthy subjects, questionnaires revealed no family history of diabetes or heart disease. Furthermore, all were free from pharmacological treatment or any diseases. All were nonsmokers and non-snuff users.

**Study Protocol**

This was a pilot study with a randomized crossover design. A scheme of the test protocol is given in Fig. 1. After a 12-h overnight fast, subjects underwent intravenous infusion of recombinant GLP-1 (2 pmol·kg⁻¹·min⁻¹; Restoragen, Lincoln, NE) or saline (0.9% NaCl; Baxter, Deerfield, IL) with an insulin pump (Medtronic, Minneapolis, MN) in a single-blind (blinded for patient) random crossover study, with a washout period of 1 wk. Subjects were not allowed to eat or drink anything but water, and they refrained from their medicines on the morning of the test day; otherwise, subjects were taking their medicines as usual between the two procedures.
and changes in arterial vasodilation were done unaware of the subjects or the procedure.

The mean (SE; range) coefficients of repeatability and variance were determined in all subjects (pooled data) between the first and second visit at basal condition, according to guidelines for ultrasound assessment (10). The mean (SE; range) for FMD(%) was 6.0 (1.3; 3.3–8.7) at the first visit and 7.0 (1.1; 4.6–9.3) at the second visit. The mean (SE; range) for NTG(%) was 18.4 (1.3; 15.8–20.1) at the first visit and 15.6 (1.3; 12.9–18.2) at the second visit. Correlation (r) between the first and second visit was \( r = 0.8 \) for FMD(%) and \( r = 0.6 \) for NTG(%). Repeatability coefficients (RCs) were calculated with the formula \( RC = 2\sqrt{\Delta D/n} \), where \( D_1 \) is the absolute difference between measurements at first and second visit, and \( n \) is the number of measurements (5). RC was 7.1 for FMD(%) and 11.9 for NTG(%). Correlation of variation between the first and second visit was 9.8% and 14.7% for FMD(%) and NTG(%), respectively.

**Hyperinsulinemic Isoglycemic Glucose Clamp**

Hyperinsulinemic clamp were performed according to DeFronzo et al. (12). In brief, a superficial dorsal hand vein was cannulated in retrograde fashion with a 21-gauge butterfly needle and kept patent by a slow infusion of saline solution. The hand was kept warm by an electric device for intermittent sampling of arterialized venous blood. After that, one intravenous catheter was inserted into the left antecubital vein for substrate (insulin/glucone) and drug infusion (GLP-1/saline). During the 120 min of the test, insulin (40 mU·m⁻²·min⁻¹ Human Actrapid; Novo Nordisk, Bagsvaerd, Denmark) was infused along with 20% dextrose (Fresenius Kabi, Copenhagen, Denmark). The rate of dextrose infusion was adjusted to achieve a blood glucose concentration of 5% nonfat dry milk, followed by an overnight incubation with 5 μg/ml of rabbit anti-NH₂-terminal GLP-1 receptor antibody (a generous gift of Dr. Bernard Thorens) in TBS-T-1% BSA at 4°C. The membrane was further incubated with horseradish peroxidase-labeled goat anti-rabbit IgG in TBS-T-1% BSA for 1 h at room temperature. The immunostained proteins were visualized by enhanced chemiluminescence (21).

**Analytical Methods**

Blood glucose levels were determined by the glucose oxidase method with a glucose analyzer (2300 STAT PLUS; Yellow Springs Instruments, Yellow Springs, OH). Arterialized plasma samples were anticoagulated with EDTA, centrifuged for ~15 min, separated, and stored at ~20°C until assayed. Plasma samples for each subject were run in the same assay to eliminate interassay variations. Insulin and C-peptide were measured with the use of enzyme-linked immunosorbent assays (Pharmacia, Uppsala, and Mercodia, Uppsala, Sweden, respectively).

Total GLP-1 was determined with a radioimmunoassay using antisemur-89390, which is highly specific for the COOH terminus of GLP-1 and therefore measures the sum of GLP-1-(7–36) amide and its metabolite GLP-1-(9–36). For GLP-1 and glucagon analysis, plasma was extracted with ethanol (final concentration 70% by volume). The glucagon assay uses an antisemur directed against the COOH terminus of the glucagon molecule (antibody code no. 4305).

**Statistical Analysis**

Results are shown as means ± SE. Comparisons between treatments and time were made by analysis of variance (ANOVA) for repeated measures. Furthermore, by use of a sequence factor (regarding the order in which subjects were examined) in the ANOVA model, any carryover effects were corrected for. Significant differences by ANOVA were followed by the post hoc Sheffe’s test. Normality tests revealed that all parameters, except triglycerides, showed bell-shaped Gaussian curves. \( P < 0.05 \) was deemed statistically significant.

**RESULTS**

**Healthy Subjects**

**Hyperinsulinemic clamp data.** All data are given in Fig. 2. Basal levels of plasma insulin \([32 ± 6 \text{ vs. } 35 ± 4 \text{ pmol/l}, P = \text{not significant (NS)}]\), C-peptide \([325 ± 19 \text{ vs. } 359 ± 18 \text{ pmol/l}, P = \text{NS}]\), glucagon \([7.7 ± 1.5 \text{ vs. } 8.0 ± 1.4 \text{ pmol/l}, P = \text{NS}]\), GLP-1 \([5.0 ± 1.4 \text{ vs. } 5.0 ± 1.3 \text{ pmol/l}, P = \text{NS}]\), and blood glucose \([4.6 ± 0.1 \text{ vs. } 4.7 ± 0.1 \text{ mmol/l}, P = \text{NS}]\) were similar between GLP-1 and saline infusions. During GLP-1 infusion, plasma levels of insulin, C-peptide, and GLP-1 significantly increased, whereas plasma glucagon levels did not change (Fig. 2). At steady-state clamp, during the last 30 min, GLP-1 infusion affected neither GIR \([11.8 ± 1.0 \text{ vs. } 13.3 ± 0.7 \text{ mg·kg}^{-1}·\text{min}^{-1}, P = \text{NS}]\) nor \( S_1[14.8 ± 1.8 \text{ vs. } 11.6 ± 2.0 (10^{-3} \text{ dl·kg}^{-1}·\text{min}^{-1})/(\mu\text{U/ml}), P = \text{NS}]\).

**FMD and NTG responses.** All data are given in Table 2. Baseline brachial artery diameters for FMD and NTG were similar between GLP-1 and saline infusions, both at onset and at steady-state clamp. At steady-state clamp, brachial artery diameter tended to increase, albeit not significantly, compared with onset. FMD(%) as well as NTG(%) were above 10 and 15%, respectively. GLP-1 infusion did not affect FMD or NTG responses.

**Brachial artery flow data.** All data are given in Table 2. The postischemic stimulus measured as brachial artery blood flow did not differ between the procedures, nor did GLP-1 infusion affect brachial artery blood flow.
Heart rate and blood pressure data. Neither systolic nor diastolic blood pressure changed during GLP-1 infusion. GLP-1 infusion also did not affect heart rate (Table 2).

Type 2 Diabetes Subjects

Hyperinsulinemic clamp data. All data are given in Fig. 3. Basal levels of plasma insulin (182 ± 84 vs. 187 ± 72 pmol/l, P = NS), C-peptide (597 ± 93 vs. 533 ± 96 pmol/l, P = NS), glucagon (12.6 ± 1.3 vs. 11.3 ± 1.1 pmol/l, P = NS), GLP-1 (9.6 ± 2.1 vs. 8.4 ± 1.2 pmol/l, P = NS), and blood glucose (6.5 ± 0.7 vs. 6.4 ± 0.8 mmol/l, P = NS) were similar between GLP-1 and saline infusions. During GLP-1 infusion, plasma levels of C-peptide and GLP-1 significantly increased, whereas plasma insulin levels did not change (Fig. 3). Plasma glucagon levels decreased during GLP-1 infusion (Fig. 3). At steady-state clamp, GLP-1 infusion affected neither GIR (3.7 ± 0.3 vs. 4.2 ± 0.4 mg·kg⁻¹·min⁻¹, P = NS) nor SI [4.5 ± 0.8 vs. 5.2 ± 0.9 (10⁻⁴ dl·kg⁻¹·min⁻¹)/(µU/ml), P = NS].

FMD and NTG responses. All data are given in Table 3. Baseline brachial artery diameters for FMD and NTG were similar between GLP-1 and saline infusions, both at onset and at steady-state clamp. At steady-state clamp, brachial artery diameter tended to increase, albeit not significantly, compared with onset. There was a poor increase in FMD(%) seen in this group. However, NTG(%) seemed not to be diminished. At steady-state clamp, GLP-1 infusion significantly increased FMD(%) (3.1 ± 0.6 vs. 6.6 ± 1.0%, P < 0.05). Patients with higher blood glucose levels did not react better in FMD(%) than patients with lower blood glucose during isoglycemic clamp (blood glucose range 4.4–9.1 mmol/l).

Brachial artery flow data. All data are given in Table 3. The postischemic stimulus measured as brachial artery blood flow did not differ between the procedures, nor did GLP-1 infusion affect brachial artery blood flow.

Heart rate and blood pressure data. Neither systolic nor diastolic blood pressure changed during GLP-1 infusion. GLP-1 infusion also did not affect heart rate (Table 3).

Side Effects of GLP-1

Two of 12 subjects in the type 2 diabetes group and 3 of 10 subjects in the healthy group experienced a transient mild sensation of nausea during infusion of GLP-1 compared with saline. It is known from several clinical trials that nausea frequently occurs at pharmacological doses of GLP-1.

Human Coronary Artery Endothelial Cells Express the GLP-1 Receptor

Because there is ambiguity as to the exact location of the GLP-1 receptor in human blood vessels, we determined whether it is expressed in pure human coronary artery endothelial cells. Western blotting of the cell lysates prepared from HCAEC revealed a single band with a molecular mass of 67 kDa, corresponding to the GLP-1 receptor seen in BRIN cells. It indicates the expression of the GLP-1 receptor in the endothelial cells with less abundance than in insulin-secreting cells (Fig. 4).

Table 2. Brachial artery, heart rate, and blood pressure data in healthy subjects

<table>
<thead>
<tr>
<th>Variable</th>
<th>Onset</th>
<th>Clamp</th>
<th>Onset</th>
<th>Clamp</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline diameter FMD, mm</td>
<td>3.8 ± 0.1</td>
<td>4.0 ± 0.2</td>
<td>3.8 ± 0.2</td>
<td>4.0 ± 0.2</td>
</tr>
<tr>
<td>Maximal diameter FMD, mm</td>
<td>4.2 ± 0.2</td>
<td>4.4 ± 0.2</td>
<td>4.2 ± 0.2</td>
<td>4.4 ± 0.2</td>
</tr>
<tr>
<td>Maximal diameter NTG, mm</td>
<td>4.6 ± 0.2</td>
<td>4.6 ± 0.2</td>
<td>4.6 ± 0.2</td>
<td>4.6 ± 0.2</td>
</tr>
<tr>
<td>Maximal diameter NTG, mm</td>
<td>19.6 ± 1.2</td>
<td>16.5 ± 1.3</td>
<td>16.9 ± 1.5</td>
<td>15.2 ± 1.4</td>
</tr>
<tr>
<td>Maximal flow FMD, ml/min</td>
<td>35 ± 2</td>
<td>35 ± 2</td>
<td>37 ± 3</td>
<td>36 ± 4</td>
</tr>
<tr>
<td>Maximal flow NTG, ml/min</td>
<td>35 ± 2</td>
<td>40 ± 4</td>
<td>36 ± 3</td>
<td>40 ± 3</td>
</tr>
<tr>
<td>Heart rate, beats/min</td>
<td>52 ± 2</td>
<td>55 ± 3</td>
<td>52 ± 2</td>
<td>56 ± 3</td>
</tr>
<tr>
<td>sBP, mmHg</td>
<td>112 ± 2</td>
<td>111 ± 2</td>
<td>107 ± 1</td>
<td>108 ± 1</td>
</tr>
<tr>
<td>dBP, mmHg</td>
<td>71 ± 3</td>
<td>69 ± 2</td>
<td>72 ± 1</td>
<td>69 ± 1</td>
</tr>
</tbody>
</table>

Data are means ± SE. Brachial artery, heart rate, and blood pressure data in healthy subjects at onset and at steady-state hyperinsulinemic clamp during glucagon-like peptide-1(7–36) amide (GLP-1) or saline infusion. Onset, resting state without any procedure or infusions; Clamp, 90- to 120-min interval in hyperinsulinemic clamp; FMD, flow-mediated dilation (endothelium-dependent vasodilation); NTG, nitroglycerin-mediated dilation (endothelia-independent vasodilation); AFMD(%), relative increases in FMD; Δ NTG(%), relative increases in NTG; sBP, systolic blood pressure; dBP, diastolic blood pressure.
We report in this study the novel finding that GLP-1 improves endothelial dysfunction in type 2 diabetes subjects without affecting whole body glucose uptake. It is well known that type 2 diabetes subjects are characterized by impaired endothelial-dependent relaxation, which may be a consequence of a disturbed synthesis or increased destruction of NO or a combination thereof (8). In agreement with this, the currently studied type 2 diabetes subjects showed a poor FMD response indicative of severe endothelial dysfunction. Infusion of GLP-1 significantly improved this FMD response in type 2 diabetes subjects without any effects in healthy subjects. It has been reported that GLP-1 directly relaxes pulmonary artery vessel rings in a rat organ bath model (27). This relaxation was abolished after removal of the vascular endothelium, indicating the requirement of an intact endothelium in GLP-1 vasorelaxation (16, 27). The exact location of the GLP-1 receptor in human blood vessels has not been unequivocally shown, but our present data demonstrate that the receptor is expressed in pure human coronary artery endothelial cells. However, it remains to be studied whether GLP-1 functions as an endogenous vasodilator. GLP-1 vasorelaxation was also demonstrated by Golpon et al. (17), who suggested that this effect was NO dependent. Interestingly, chronically administered GLP-1 improves vasodilator response in preconstricted aortic rings in a salt-sensitive rodent model (34). In the present study, GLP-1 may have increased endothelial NO synthase activation, thereby improving endothelial function. However, the possibility that the amelioration of the impaired FMD by GLP-1 noted in our type 2 diabetes subjects is an effect of GLP-1 per se cannot be excluded at this point. The effect of GLP-1 on small bowel motility (31) as well as the vasorelaxant influence on the pulmonary artery (17), who suggested that this effect was NO dependent.

Table 3. Brachial artery, heart rate, and blood pressure data in type 2 diabetes subjects

<table>
<thead>
<tr>
<th>Variable</th>
<th>Saline Onset</th>
<th>Saline Clamp</th>
<th>GLP-1 Onset</th>
<th>GLP-1 Clamp</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline diameter FMD, mm</td>
<td>4.2±0.1</td>
<td>4.3±0.1</td>
<td>4.3±0.1</td>
<td>4.4±0.2</td>
</tr>
<tr>
<td>Maximal diameter FMD, mm</td>
<td>4.3±0.1</td>
<td>4.6±0.1</td>
<td>4.3±0.1</td>
<td>4.7±0.2</td>
</tr>
<tr>
<td>(\Delta) FMD(%)</td>
<td>2.0±0.7</td>
<td>3.1±0.6</td>
<td>2.2±0.5</td>
<td>6.6±1.0*</td>
</tr>
<tr>
<td>Baseline diameter NTG, mm</td>
<td>4.3±0.1</td>
<td>4.5±0.2</td>
<td>4.3±0.1</td>
<td>4.5±0.2</td>
</tr>
<tr>
<td>Maximal diameter NTG, mm</td>
<td>5.0±0.1</td>
<td>5.1±0.1</td>
<td>5.0±0.1</td>
<td>5.2±0.1</td>
</tr>
<tr>
<td>(\Delta) NTG(%)</td>
<td>17.5±2.0</td>
<td>14.5±2.0</td>
<td>16.7±1.5</td>
<td>16.5±2.4</td>
</tr>
<tr>
<td>Baseline flow FMD, ml/min</td>
<td>56±4</td>
<td>52±4</td>
<td>60±10</td>
<td>54±5</td>
</tr>
<tr>
<td>Maximal flow FMD, ml/min</td>
<td>166±9</td>
<td>161±11</td>
<td>162±12</td>
<td>167±18</td>
</tr>
<tr>
<td>Baseline flow NTG, ml/min</td>
<td>58±4</td>
<td>53±4</td>
<td>57±4</td>
<td>58±4</td>
</tr>
<tr>
<td>Maximal flow NTG, ml/min</td>
<td>64±4</td>
<td>62±3</td>
<td>67±4</td>
<td>69±4</td>
</tr>
<tr>
<td>Heart rate, beats/min</td>
<td>61±3</td>
<td>60±3</td>
<td>60±3</td>
<td>62±3</td>
</tr>
<tr>
<td>SBP, mmHg</td>
<td>127±5</td>
<td>125±4</td>
<td>124±4</td>
<td>127±3</td>
</tr>
<tr>
<td>DBP, mmHg</td>
<td>78±2</td>
<td>77±2</td>
<td>78±2</td>
<td>78±2</td>
</tr>
</tbody>
</table>

Data are means ± SE. Brachial artery, heart rate, and blood pressure data in type 2 diabetes subjects at onset and at steady-state hyperinsulinemic clamp during GLP-1 or saline infusion. See Table 2 legend for additional information. *P < 0.05 compared with saline (onset and clamp) and with GLP-1 (onset), ANOVA.

DISCUSSION

We report in this study the novel finding that GLP-1 improves endothelial dysfunction in type 2 diabetes patients with established coronary artery disease without affecting whole body glucose uptake. It is well known that type 2 diabetes subjects are characterized by impaired endothelial-dependent relaxation, which may be a consequence of a disturbed synthesis or increased destruction of NO or a combination thereof (8). In agreement with this, the currently studied type 2 diabetes subjects showed a poor FMD response indicative of severe endothelial dysfunction. Infusion of GLP-1 significantly improved this FMD response in type 2 diabetes subjects without any effects in healthy subjects. It has been reported that GLP-1 directly relaxes pulmonary artery vessel rings in a rat organ bath model (27). This relaxation was abolished after removal of the vascular endothelium, indicating the requirement of an intact endothelium in GLP-1 vasorelaxation (16, 27). The exact location of the GLP-1 receptor in human blood vessels has not been unequivocally shown, but our present data demonstrate that the receptor is expressed in pure human coronary artery endothelial cells. However, it remains to be studied whether GLP-1 functions as an endogenous vasodilator. GLP-1 vasorelaxation was also demonstrated by Golpon et al. (17), who suggested that this effect was NO dependent. Interestingly, chronically administered GLP-1 improves vasodilator response in preconstricted aortic rings in a salt-sensitive rodent model (34). In the present study, GLP-1 may have increased endothelial NO synthase activation, thereby improving endothelial function. However, the possibility that the amelioration of the impaired FMD by GLP-1 noted in our type 2 diabetes subjects is an effect of GLP-1 per se cannot be excluded at this point. The effect of GLP-1 on small bowel motility (31) as well as the vasorelaxant influence on the pulmonary artery (17) is NO dependent.

It has become increasingly clear that insulin also has vasoreactive properties that are NO dependent (28) and diminished in insulin-resistant states (29). However, in the present study, plasma insulin levels during the hyperinsulinemic clamp were identical between GLP-1 and saline infusions in type 2 diabetes subjects. Therefore, the salutary effect on endothelial function of GLP-1 seen in our type 2 diabetes subjects is an effect of GLP-1 per se cannot be excluded at this point. The effect of GLP-1 on small bowel motility (31) as well as the vasorelaxant influence on the pulmonary artery (17) is NO dependent.
GLP-1 infusion. Nonetheless, the difference in plasma insulin levels between saline and GLP-1 infusions in healthy subjects makes it difficult to determine whether GLP-1 also may affect a normal, functional endothelium.

Endothelial dysfunction is associated with insulin resistance and type 2 diabetes mellitus and may be causing the angiopathy typifying this debilitating disease. Improvement of insulin resistance may also improve endothelial function. Recently, it was shown that long-term treatment with GLP-1 enhances both insulin sensitivity and β-cell function in type 2 diabetic patients along with secondary metabolic improvements, e.g., reduced glucotoxicity and lowering of free fatty acids (35). However, these authors could not rule out a direct effect of GLP-1 on the improved insulin sensitivity (35). In our type 2 diabetes subjects, there was a relative increase of 16% in insulin sensitivity, albeit not significant. This could in part be an issue of a beta-error, because the correlation of variation in the clamp method is reported to be 15% compared with that in the ultrasound method (10%) in the current study. However, in short-term studies, GLP-1 does not seem to affect insulin sensitivity (1, 25), lending support to our present findings. Therefore, it seems unlikely that the improvement in endothelial function is secondary to the small increase in insulin sensitivity index seen in type 2 diabetes patients.

A robust increase in C-peptide levels was seen after GLP-1 administration in both groups. There are reports showing an increase in blood flow in patients with type 1 diabetes after C-peptide infusion, supporting the view that C-peptide elicits NO-dependent vascular effects (15, 20). However, in these studies, C-peptide levels were as much as four times higher compared with our present study. Furthermore, it remains to be proven that C-peptide increases blood flow in type 2 diabetes subjects with cardiovascular disease. Thus, although these differences make it difficult to compare these findings with the present results, the possibility remains that the increased blood flow by GLP-1 observed in our study could partly be mediated by the increase in C-peptide levels.

No changes were seen in blood pressure or heart rate during GLP-1 infusion. Recent rat studies have demonstrated an increase in systolic and diastolic blood pressure during GLP-1 treatment, an effect believed to be mediated by a central increase in sympathetic outflow (3, 4, 33). Concerns have therefore been raised as to whether GLP-1 may be suitable for type 2 diabetic patients, in whom hypertension is common and adversely influences their survival (33). In contrast, Yu et al. (34) demonstrated antihypertensive effects by chronic GLP-1 treatment in a rat model. In a human study, continuous GLP-1 infusion tended to lower both systolic and diastolic blood pressure (30). The reason for the apparent discrepancies is not clear, although differences in species, dose, and treatment duration may be involved. Our findings nonetheless do not support previous concerns about blood pressure raising actions of GLP-1.

In conclusion, we show here for the first time that GLP-1 ameliorates endothelial dysfunction in type 2 diabetic patients with an established coronary artery disease. This beneficial vascular effect of GLP-1 adds yet another salutary property of the peptide, increasing its clinical utility in type 2 diabetic patients, in whom endothelial dysfunction is a salient feature that adversely affects their survival.

ACKNOWLEDGMENTS

We thank Lotta Larsson and Christina Hall for excellent technical assistance. We thank Dr. Bernard Thorens for graciously donating the GLP-1 receptor antibody. Recombinant human GLP-1(7–36)amide was a kind gift from Restogen.

GRANTS

Financial support was received from the Swedish Medical Research Council (Grants 72X-12550, 72X-14507, and 72P-14787), the Nutricia Research Foundation, the European Foundation for the Study of Diabetes, the Sigurd and Elsa Golje Memorial Foundation, Svenska Försäkringsföreningen, Svenska Diabetesstiftelsen, Berth von Kantzow’s Foundation, and Stiftelsen Serafimerlassaretet.

REFERENCES


